Active Cues Competitors

Luminus is a vertically integrated fast-growing high-tech company that engages in high power Light-Emitting-Diode (LED) solid-state lighting for a variety of application areas such as industrial UV, IR, medicals, projection displays, high-end illumination lighting, horticulture lighting and automotive lighting. Luminus is at the forefront of the undergoing solid-state lighting revolution that will change the lighting technology in almost every aspect of our everyday work and life.

CaringBridge is a no-cost, 501(c)(3) nonprofit health platform that surrounds family caregivers with support while they care for a loved one on a health journey. A donor-supported nonprofit founded in 1997, the organization offers tools to share and document a health journey, simplify care coordination, and connect caregivers with a supportive community.

Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com.